Related Experiment Video
Updated: May 23, 2026
09:44
High-throughput Screening for Chemical Modulators of Post-transcriptionally Regulated Genes
Published on: March 3, 2015
[High-throughput screening for hamster chymase 2 inhibitors]
Shou-Bao Wang1, Xiao-Ming Zhu, Feng Gao
1National Center for Pharmaceutical Screening, Institute of Materia Medica, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China.
Yao Xue Xue Bao = Acta Pharmaceutica Sinica
|April 19, 2012
Summary
Researchers developed a sensitive high-throughput screening (HTS) model to find hamster chymase 2 inhibitors. Two compounds, J16647 and J16648, showed significant inhibitory activity, paving the way for new therapeutic strategies.
Area of Science:
- Biochemistry
- Enzymology
- Drug Discovery
Background:
- Hamster chymase 2 is a target enzyme for potential therapeutic interventions.
- Developing efficient screening methods is crucial for identifying novel enzyme inhibitors.
Purpose of the Study:
- To establish and validate a high-throughput screening (HTS) model for identifying hamster chymase 2 inhibitors.
- To screen a large library of compounds and natural products for inhibitory activity against hamster chymase 2.
Main Methods:
- Cloning and expression of active recombinant hamster chymase 2 in E. coli.
- Development of a fluorescence-based HTS assay in 384-well microplates (50 microL total volume).
- Screening of 40,080 samples (28,060 compounds, 12,020 natural products) followed by rescreening of hits.
Main Results:
- The HTS model demonstrated high sensitivity and specificity (Z' = 0.84).
- 613 samples exhibited >90% inhibition and proceeded to rescreening.
- Compounds J16647 and J16648 were identified as potent inhibitors with IC50 values of 0.823 and 0.690 microM, respectively.
Conclusions:
- A robust and validated HTS platform for hamster chymase 2 inhibition screening was successfully established.
- The study identified two novel, potent inhibitors of hamster chymase 2, J16647 and J16648.
- These findings provide a foundation for further development of chymase 2-targeted therapeutics.
